Bendamustine interactions
Full monograph for BendamustineCheck it against another medicine
Medicines
106 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Adalimumab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Baricitinib | Major | Synergy | Coadministration of baricitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies… | 4 sources — open the full entry |
| Clozapine | Major | Synergy | Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. | 9 sources — open the full entry |
| Deferiprone | Major | Synergy | Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity… | 5 sources — open the full entry |
| Etanercept | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Golimumab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Infliximab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Leflunomide | Major | Synergy | The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to… | 2 sources — open the full entry |
| Rotavirus Vaccine | Major | Others | The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of… | 9 sources — open the full entry |
| Tofacitinib | Major | Others | Coadministration of tofacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies… | 1 sources — open the full entry |
| Upadacitinib | Major | Others | Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. | 1 sources — open the full entry |
| Yellow Fever Vaccine | Major | Others | The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of…2 documented mechanisms | 19 sources — open the full entry |
| Abametapir | Moderate | Metabolism | Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450… | 1 sources — open the full entry |
| Albendazole | Moderate | Metabolism | Coadministration with inducers of CYP450 1A2 may decrease the plasma concentrations of bendamustine and increase the plasma concentrations of its… | 1 sources — open the full entry |
| Allopurinol | Moderate | Synergy | Coadministration of bendamustine with allopurinol may increase the risk of severe skin reactions. The potential mechanism of interaction has not been… | 2 sources — open the full entry |
| Amiodarone Hydrochloride | Moderate | Metabolism | Coadministration with inhibitors of CYP450 1A2 may increase the plasma concentrations of bendamustine, which has been shown in vitro to be metabolized by the… | 1 sources — open the full entry |
| Azathioprine | Moderate | Synergy | The use of azathioprine with other immunosuppressive or myelosuppressive agents may result in additive hematologic toxicities and increased risk of infections… | 3 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of… | 8 sources — open the full entry |
| Beta carotene + Vitamin C + Vitamin E | Moderate | Others | The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses… | 9 sources — open the full entry |
| Bleomycin Sulfate | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Caffeine Citrate | Moderate | Metabolism | Coadministration with inhibitors of CYP450 1A2 may increase the plasma concentrations of bendamustine, which has been shown in vitro to be metabolized by the… | 1 sources — open the full entry |
| Capecitabine | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Capmatinib Hydrochloride | Moderate | Metabolism | Coadministration with inhibitors of CYP450 1A2 may increase the plasma concentrations of bendamustine, which has been shown in vitro to be metabolized by the… | 1 sources — open the full entry |
| Carbamazepine | Moderate | Metabolism | Coadministration with inducers of CYP450 1A2 may decrease the plasma concentrations of bendamustine and increase the plasma concentrations of its… | 1 sources — open the full entry |
| Carboplatin | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Carmustine | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Chlorambucil | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Chloramphenicol (Ophthalmic) | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of… | 8 sources — open the full entry |
| Chloramphenicol (Oral) | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of… | 8 sources — open the full entry |
| Chloramphenicol + Lidocaine Hydrochloride | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of… | 8 sources — open the full entry |
| CiprofloxacinbaseOphthalmic | Moderate | Metabolism | Coadministration with inhibitors of CYP450 1A2 may increase the plasma concentrations of bendamustine, which has been shown in vitro to be metabolized by the… | 1 sources — open the full entry |
| Ciprofloxacin + Dexamethasone | Moderate | Metabolism | Coadministration with inhibitors of CYP450 1A2 may increase the plasma concentrations of bendamustine, which has been shown in vitro to be metabolized by the… | 1 sources — open the full entry |
| Ciprofloxacin + Hydrocortisone Acetate | Moderate | Metabolism | Coadministration with inhibitors of CYP450 1A2 may increase the plasma concentrations of bendamustine, which has been shown in vitro to be metabolized by the… | 1 sources — open the full entry |
| Cisplatin | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Cyclophosphamide | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Cytarabine | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Dacarbazine | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Daunorubicin | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Decitabine | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Deferasirox | Moderate | Metabolism | Coadministration with inhibitors of CYP450 1A2 may increase the plasma concentrations of bendamustine, which has been shown in vitro to be metabolized by the… | 1 sources — open the full entry |
| Denosumab | Moderate | Synergy | Concomitant use of immunosuppressive or myelosuppressive agents with denosumab may increase the risk of serious infections. Denosumab binds to and inhibits the… | 2 sources — open the full entry |
| Dexamethasone + Chloramphenicol | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of… | 8 sources — open the full entry |
| Diphtheria + Tetanus + Pertussis + Hepatitis B + Polio + HIB | Moderate | Antagonism | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a… | 10 sources — open the full entry |
| Diroximel Fumarate | Moderate | Synergy | The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may… | 1 sources — open the full entry |
| Docetaxel Trihydrate | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Doxorubicin Hydrochloride | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Doxorubicin Hydrochloride Liposome | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Epirubicin Hydrochloride | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| EsomeprazolebaseMUPS preparation | Moderate | Metabolism | Coadministration with inducers of CYP450 1A2 may decrease the plasma concentrations of bendamustine and increase the plasma concentrations of its… | 1 sources — open the full entry |
| Esomeprazole + Amoxicillin + Clarithromycin | Moderate | Metabolism | Coadministration with inducers of CYP450 1A2 may decrease the plasma concentrations of bendamustine and increase the plasma concentrations of its… | 1 sources — open the full entry |
Conditions
Conditions in which Bendamustine needs care, as documented in this source.
Hepatic Insufficiency
MajorBendamustine injection should be used with caution in patients with hepatic impairment. Bendamustine injection should not be used in patients with moderate (AST or ALT 2.5 to 10 X ULN and total bilirubin 1.5 to 3 X ULN) or severe (total bilirubin greater than 3 X ULN) hepatic impairment.
1 source
- "Product Information. Treanda (bendamustine)." Cephalon Inc (2008):
Kidney Diseases
MajorBendamustine injection should be used with caution in patients with mild or moderate renal impairment. Bendamustine injection should not be used in patients with CrCL < 40 mL/min.
1 source
- "Product Information. Treanda (bendamustine)." Cephalon Inc (2008):
Bone Marrow Failure Disorders
ModerateAdult and pediatric patients treated with bendamustine have experienced Infection, including pneumonia, sepsis, septic shock, and death. Patients with myelosuppression following treatment with bendamustine hydrochloride are more susceptible to infections. Therapy with bendamustine should be administered cautiously in patients with compromised bone marrow reserve. Monitor complete blood counts, including leukocytes, platelets, hemoglobin (Hgb), and neutrophils frequently.
1 source
- "Product Information. Treanda (bendamustine)." Cephalon Inc (2008):
Infections
ModerateInfection, including pneumonia, sepsis, septic shock, hepatitis, and death has occurred in adult and pediatric patients treated with bendamustine. Care should be exercised when using this drug in patients whose bone marrow reserve may be severely depressed as these patients could be more susceptible to infections. Patients treated with this drug are at risk for reactivation of infections including (but not limited to) hepatitis B, cytomegalovirus, Mycobacterium tuberculosis, and herpes zoster. It is recommended to advise patients with myelosuppression following treatment with this agent to contact a physician immediately if they have symptoms or signs of infection. Before starting treatment, patients should undergo appropriate measures (including clinical and laboratory monitoring, prophylaxis, and treatment) for infection and infection reactivation risks.
2 sources
- "Product Information. Treanda (bendamustine)." Cephalon Inc (2008):
- "Product Information. Bendeka (bendamustine)." Teva Pharmaceuticals USA (2016):